

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
9 September 2005 (09.09.2005)

PCT

(10) International Publication Number
WO 2005/082937 A3

(51) International Patent Classification⁷: **C07K 16/06**,
A61L 2/00

(21) International Application Number:
PCT/EP2005/050812

(22) International Filing Date:
25 February 2005 (25.02.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/548,107 27 February 2004 (27.02.2004) US

(71) Applicant (for all designated States except US): **OC-TAPHARMA AG** [CH/CH]; Seidenstrasse 2, CH-8853 Lachen (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BUCHACHER, Andrea** [AT/AT]; Saliergasse 18/5, A-1180 Wien (AT). **IBERER, Günther** [AT/AT]; Lindengasse 5/5/8, A-2331 Vösendorf (AT). **RÖMISCH, Jürgen** [DE/AT]; Beeren-gasse 1, A-2440 Gramatneusiedl (AT).

(74) Agents: **MEYERS, Hans-Wilhelm** et al.; P.O. Box 10 22 41, 50462 Cologne (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
17 November 2005

(48) Date of publication of this corrected version:
23 February 2006

(15) Information about Correction:
see PCT Gazette No. 08/2006 of 23 February 2006, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: A METHOD OF PROVIDING A PURIFIED, VIRUS SAFE ANTIBODY PREPARATION

(57) Abstract: A method of preparing a purified, virus inactivated and virus safe antibody preparation from a starting solution comprising antibodies and contaminants, the method comprising the steps of: (a) adjusting the pH of the starting solution to about 4.6 to about 4.95 in particular to about 4.8 to about 4.95 to produce an intermediate solution; (b) adding caprylate and/or heptanoate ions to the intermediate solution and maintaining the pH at about 4.6 to about 4.95 in particular pH at about 4.8 to about 4.95, whereby a precipitate is formed and the antibodies are essentially present in the supernatant; (c) incubating the supernatant solution under conditions of caprylate and/or heptanoate ion concentration, time, pH and temperature optionally concentrating and diafiltrating the filtrated solution before pH adjustment; (d) applying the filtered solution with a least one anion exchange resin and optionally with two different anion exchange resins under conditions that allow binding of contaminants to the resin while not allowing significant binding of the antibodies to the resin, wherein a purified, virus inactivated and virus safe antibody preparation is produced.

WO 2005/082937 A3